natgillin/translations-raw huggingface dataset:
Therefore, REYATAZ with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3).
Seega on REYATAZ/ritonaviir vastunäidustatud koos ravimitega, mis on CYP3A4 substraadid ning kitsa terapeutilise indeksiga nagu astemisool, terfenadiin, tsisapriid, pimosiid, kinidiin, bepridiil, triasolaam, suukaudselt manustatav midasolaam ning tungaltera alkaloidid, eeskätt ergotamiin ja dihüdroergotamiin (vt lõik 4.3).
Therefore, Soliris should be given to a pregnant woman only if clearly needed.
Seega ei tohi Soliris’t kasutada raseduse ajal, kui see ei ole hädavajalik.
Therefore, special precautions should be taken by people whose dogs have been treated with Recuvyra.
Seetõttu tuleb Recuvyra’ga ravitud koerte omanike poolt rakendada erilisi ettevaatusabinõusid.
Therefore, Spectrila must not be used during breast-feeding.
Seetõttu ei tohi Spectrila’t kasutada imetamise ajal.
Therefore, starting or ending treatment with St John’s wort should be done with caution.
Seetõttu on ravi alustamisel või lõpetamisel liht-naistepunaga vajalik ettevaatus.
Therefore, starting or ending treatment with these enzyme inducers should be done with caution.
Seetõttu on vajalik selliste ensüümi indutseerijatega ravi alustada ja lõpetada ettevaatusega.
Therefore, Stribild is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Seetõttu ei soovitata Stribild’i kasutada raske maksafunktsiooni kahjustusega patsientidel (vt lõigud 4.4 ja 5.2).
Therefore, such co- administration is not recommended.
Seetõttu ei ole nende koosmanustamine soovitatav.
Therefore, such co- administration is not recommended.
Seetõttu ei ole nende samaaegne manustamine soovitatav.
Therefore, tell your doctor if you are taking any of the following medicines: ritonavir or saquinavir (medicines for the treatment of HIV infections);
Rääkige oma arstile, kui võtate mõnda allnimetatud ravimit: ritonaviir või sakvinaviir (HIV infektsiooni raviks kasutatavad teatud ravimid);
Therefore, tenofovir disoproxil fumarate should only be used if the potential benefits of treatment are considered to outweigh the potential risks.
Seetõttu võib tenofoviirdisoproksiilfumaraati kasutada ainult sel juhul, kui leitakse, et ravi võimalik kasu on suurem sellega kaasnevatest võimalikest ohtudest.
Therefore, Teysuno cannot be used as a substitute for other oral 5-FU products.
Seetõttu ei tohi Teysuno’t kasutada teiste suukaudsete 5-FU preparaatide asemel.
Therefore, Teysuno should not be administered to children or adolescents under 18 years of age.
Seepärast ei tohi Teysuno’t manustada lastele ja noorukitele vanuses kuni 18 aastat.
Therefore, the ability of patients with dementia on rivastigmine to continue driving or operating complex machines should be routinely evaluated by the treating physician.
Seetõttu peab raviarst reeglipäraselt hindama rivastigmiin–ravi saavate dementsusega patsientide võimet juhtida autot või töötada masinatega.
Therefore, the Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that there are no clinically meaningful differences between Inhixa and Clexane in terms of effectiveness and safety and took the view that, as for Clexane, the benefit outweighs the identified risk.
Seetõttu oli inimravimite komitee arvamusel, et Inhixa ja Clexane vahel puuduvad efektiivsuse ja ohutuse osas kliiniliselt olulised erinevused, ning leidis, et nagu ka Clexane korral, ületab ravimi Inhixa kasulikkus sellega kaasnevad riskid.
Therefore, the Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that there are no clinically meaningful differences between Thorinane and Clexane in terms of effectiveness and safety and took the view that, as for Clexane, the benefit outweighs the identified risk.
Seetõttu oli inimravimite komitee arvamusel, et Thorinane ja Clexane vahel puuduvad efektiivsuse ja ohutuse osas kliiniliselt olulised erinevused, ning leidis, et nagu ka Clexane korral, ületab Thorinane kasulikkus sellega kaasnevad riskid.
Therefore, the Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Respreeza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Seetõttu otsustas inimravimite komitee, et Respreeza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
Therefore, the CHMP concluded that Flebogamma DIF’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee järeldas seega, et ravimi Flebogamma DIF kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
Therefore, the CHMP concluded that Kiovig’s benefits are greater than its risks and recommended that Kiovig be given marketing authorisation.
Inimravimite komitee järeldas seega, et Kiovigi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
Therefore, the CHMP concluded that the benefits of Zytiga were greater than its risks, and recommended it be granted marketing authorisation.
Seepärast järeldas inimravimite komitee, et Zytiga kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Adcetris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Adcetrise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Bexsero’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas seetõttu, et Bexsero kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
Therefore, the CHMP decided that Bretaris Genuair’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Bretaris Genuairi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Cuprymina’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Cuprymina kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
Therefore, the CHMP decided that Cyanokit’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Cyanokiti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Eklira Genuair’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Eklira Genuairi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Enurev Breezhaler’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seepärast otsustas inimravimite komitee, et Enurev Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Eylea’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Eylea kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Firmagon’s benefits are greater than its risks for the treatment of adult male patients with advanced hormone-dependent prostate cancer.
Inimravimite komitee jõudis seega otsusele, et Firmagoni kasulikkus kaugelearenenud hormoonsõltuva eesnäärmevähiga täiskasvanud meeste ravis on suurem kui ravimiga kaasnevad riskid.
Therefore, the CHMP decided that Fycompa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Fycompa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Orfadin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Orfadini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Revestive’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Revestive kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Sancuso’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee on seetõttu arvamusel, et Sancuso kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Seebri Breezhaler’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seepärast otsustas inimravimite komitee, et Seebri Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that the benefits of Nimenrix are greater than its risks and recommended that it be granted marketing authorisation.
Inimravimite komitee otsustas seetõttu, et Nimenrixi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda vaktsiini müügiloa.
Therefore, the CHMP decided that Thymanax’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seepärast otsustas inimravimite komitee, et Thymanaxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Tovanor Breezhaler’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seepärast otsustas inimravimite komitee, et Tovanor Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Valdoxan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Seepärast otsustas inimravimite komitee, et Valdoxani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Therefore, the CHMP decided that Vibativ’s benefits are only greater than its risks for patients who are severely ill with nosocomial pneumonia and are under close observation in hospital, and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Vibativi kasulikkus on suurem kui sellega kaasnevad riskid ainult patsientidel, kellel on raskekujuline nosokomiaalne kopsupõletik ja keda jälgitakse hoolikalt haiglas, ning soovitas anda ravimi müügiloa.
Therefore, the CHMP’s view was that, as for Abilify, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Abilify korral, ületab ravimi Aripiprazole Accord kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Abilify, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Abilify korral, ületab ravimi Aripiprazole Mylan Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Abilify, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Abilify korral, ületab ravimi Aripiprazole Sandoz kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Abilify, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Abilify korral, ületab ravimi Aripiprazole Zentiva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aclasta, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aclasta korral, ületab ravimi Zoledronic acid Teva Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aclasta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu Aclasta korral, ületab ravimi Zoledronic acid Teva Generics kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Pioglitazone Accordi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Pioglitazone Krka kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Pioglitazone Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Pioglitazone Teva Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab ravimi Pioglitazone Actavis Group kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Sepioglini kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Actose korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Actos, the benefits outweigh the identified risks.
Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab ravimi Glidipioni kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aerius, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aeriuse korral, ületab Dasselta kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aerius, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aeriuse korral, ületab Desloratadine Actavise kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aerius, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aeriuse korral, ületab Desloratadine ratiopharmi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aerius, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aeriuse korral, ületab Desloratadine Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu Alimta korral, ületab ka ravimi Pemetrexed Accord kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu Alimta korral, ületab ka ravimi Pemetrexed Fresenius Kabi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu Alimta puhul, ületab ka Armisarte kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Alimta korral, ületab ravimi Ciambra kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Alimta korral, ületab ravimi Pemetrexed Hospira kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Alimta korral, ületab ravimi Pemetrexed Lilly kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Alimta korral, ületab ravimi Pemetrexed medac kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Alimta korral, ületab ravimi Pemetrexed Sandoz kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aloxi, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aloxi korral, ületab Palonosetron Hospira kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aloxi, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aloxi korral, ületab ravimi kasulikkus sellega kaasnevaid riske.
Therefore, the CHMP’s view was that, as for Ammonaps, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Ammonapsi korral, ületab Pheburane kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aprovel, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aproveli korral, ületab Irbesartan Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aprovel, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Aproveli korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Aprovel, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Aproveli korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Arava korral, ületab Leflunomide ratiopharmi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Arava korral, ületab Repso kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Arava korral, ületab Leflunomide medaci kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Arava, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Arava korral, ületab Leflunomide Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Axura, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Axura korral, ületab ravimi Memantine LEK kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Axura, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Axura korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Azilect, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Azilecti korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Bondronat and Bonviva, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Bondronati ja Bonviva korral, ületab Ibandronic Acid Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Bondronat, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Bondronati korral, ületab Iasiboni kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Bondronat, the benefit outweighs the identified risk.
Seetõttu oli inimravimite komitee arvamusel, et nagu ka Bondronati korral, ületab Ibandronic Acid Sandozi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Busilvex, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Busilvexi korral, ületab ravimi Busulfan Fresenius Kabi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Cancidas, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu Cancidasi korral, ületab ka ravimi Caspofungin Accord kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Cellcept, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu Cellcepti korral, ületab Myclauseni kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for CellCept, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu CellCepti korral, ületab Mycophenolate mofetil Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for CellCept, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu CellCepti korral, ületab Myfenaxi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Cialis, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Cialise korral, ületab ravimi Tadalafil Mylan kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for CoAprovel, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka CoAproveli korral, ületab ravimi Ifirmacombi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for CoAprovel, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka CoAproveli korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Combivir, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Combiviri korral, ületab kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Comtess, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Comtessi korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Cymbalta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Cymbalta korral, ületab ravimi Duloxetine Mylan kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Cymbalta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Cymbalta korral, ületab ravimi Duloxetine Zentiva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Ebixa, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Ebixa korral, ületab Nemdatine kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Ebixa, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Ebixa korral, ületab ravimi Marixino kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Ebixa, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Ebixa korral, ületab ravimi Memantine Mylan kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Ebixa, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Ebixa korral, ületab ravimi Memantine ratiopharm kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Epivir, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Epiviri korral, ületab ravimi kasulikkus sellega kaasnevad riskid.